| Literature DB >> 29078330 |
Barbara Ludwig1,2,3, Stefan Ludwig4, Anja Steffen5,2,3, Yvonne Knauf6, Baruch Zimerman7, Sophie Heinke8, Susann Lehmann5, Undine Schubert5, Janine Schmid5, Martina Bleyer6, Uwe Schönmann6, Clark K Colton9, Ezio Bonifacio10, Michele Solimena2,3,11, Andreas Reichel5, Andrew V Schally12,13,14,15,16,17, Avi Rotem7, Uriel Barkai7, Helena Grinberg-Rashi7, Franz-Josef Kaup6, Yuval Avni7, Peter Jones18, Stefan R Bornstein5,2,3,18.
Abstract
Transplantation of pancreatic islets for treating type 1 diabetes is restricted to patients with critical metabolic lability resulting from the need for immunosuppression and the shortage of donor organs. To overcome these barriers, we developed a strategy to macroencapsulate islets from different sources that allow their survival and function without immunosuppression. Here we report successful and safe transplantation of porcine islets with a bioartificial pancreas device in diabetic primates without any immune suppression. This strategy should lead to pioneering clinical trials with xenotransplantation for treatment of diabetes and, thereby, represents a previously unidentified approach to efficient cell replacement for a broad spectrum of endocrine disorders and other organ dysfunctions. Published under the PNAS license.Entities:
Keywords: beta-cell replacement; diabetes; immune barrier; porcine islets
Mesh：
Year: 2017 PMID： 29078330 PMCID： PMC5676906 DOI： 10.1073/pnas.1708420114
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205